rstrip ii exponential curve stripping and parameter estimation program version 2.02 (MicroMath Inc)
90
Structured Review
MicroMath Inc
rstrip ii exponential curve stripping and parameter estimation program version 2.02
Rstrip Ii Exponential Curve Stripping And Parameter Estimation Program Version 2.02, supplied by MicroMath Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rstrip+ii+exponential+curve+stripping+and+parameter+estimation+program+version+2%2E02/rstrip+ii+exponential+curve+stripping+and+parameter+estimation+program+version+2+02/pm12655436-73-28-31
Average 90 stars, based on 1 article reviews
Rstrip Ii Exponential Curve Stripping And Parameter Estimation Program Version 2.02, supplied by MicroMath Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rstrip+ii+exponential+curve+stripping+and+parameter+estimation+program+version+2%2E02/rstrip+ii+exponential+curve+stripping+and+parameter+estimation+program+version+2+02/pm12655436-73-28-31
Average 90 stars, based on 1 article reviews
rstrip ii exponential curve stripping and parameter estimation program version 2.02 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome. Article Snippet: Purpose: Quinocarmycin analog DX-52-1 is a cyanated derivative of quinocarmycin, a compound isolated from cultures of Streptomyces melanovinaceus.. DX-52-1 was selected for preclinical development because it showed efficacy against melanoma cell lines in the NCI human tumor cell screen and melanoma xenografts in mice.. This report describes studies in rats and dogs to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLT) in each species in different regimens to establish a safe starting dose and potential target organs of DX-52-1 for phase I clinical trials. Stripping Membranes:Article Title: Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome. Article Snippet: Purpose: Quinocarmycin analog DX-52-1 is a cyanated derivative of quinocarmycin, a compound isolated from cultures of Streptomyces melanovinaceus.. DX-52-1 was selected for preclinical development because it showed efficacy against melanoma cell lines in the NCI human tumor cell screen and melanoma xenografts in mice.. This report describes studies in rats and dogs to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLT) in each species in different regimens to establish a safe starting dose and potential target organs of DX-52-1 for phase I clinical trials. Software:Article Title: Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome. Article Snippet: Purpose: Quinocarmycin analog DX-52-1 is a cyanated derivative of quinocarmycin, a compound isolated from cultures of Streptomyces melanovinaceus.. DX-52-1 was selected for preclinical development because it showed efficacy against melanoma cell lines in the NCI human tumor cell screen and melanoma xenografts in mice.. This report describes studies in rats and dogs to determine the maximum tolerated dose (MTD) and identify dose-limiting toxicities (DLT) in each species in different regimens to establish a safe starting dose and potential target organs of DX-52-1 for phase I clinical trials. |